NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Masitinib for treating unresectable or metastatic gastrointestinal stromal tumours after treatment with imatinib

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors AB Science (masitinib) Patient/carer groups Afiya Trust Beating Bowel Cancer Black Health Agency Bladder and Bowel Foundation Bowel Cancer Information (formerly Lynn's Bowel Cancer Campaign) Bowel Cancer UK Cancer Black Care Cancer Equality Cancer52 Equalities National Council GIST Support UK Helen Rollason Cancer Charity	 General Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Commissioning Support Appraisals Service Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Alliance NHS Commercial Medicines Unit
 Independent Cancer Patient's Voice Macmillan Cancer Support Maggie's Centres Marie Curie Cancer Care Muslim Council of Britain Muslim Health Network 	 NHS Confederation Scottish Medicines Consortium Comparator manufacturer(s) Pfizer (sunitinib)
 Muslim Health Network Ochre Oesophageal Patients Association Rarer Cancers Foundation Sarcoma UK South Asian Health Foundation Specialised Healthcare Alliance Tenovus Professional groups Association of Cancer Physicians Association of Surgeons of Great 	 Relevant research groups Bowel & Cancer Research Cochrane Upper Gastrointestinal and Pancreatic Diseases Group CORE (Digestive Disorders Foundation) Health Research Authority Institute of Cancer Research MRC Clinical Trials Unit National Cancer Research Institute National Cancer Research Network National Institute for Health Research

National Institute for Health and Care Excellence

Matrix for the appraisal of masitinib for treating unresectable or metastatic gastrointestinal stromal tumours after treatment with imatinib

Issue date: September 2013

Consultees	Commentators (no right to submit or appeal)
 Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland British Association for Services to the Elderly British Association of Surgical Oncology British Geriatric Society British Institute of Radiology British Psychosocial Oncology Society British Society of Gastroenterology Cancer Network Pharmacists Forum Cancer Research UK Royal College of General Practitioners Royal College of Pathologists Royal College of Pathologists Royal College of Radiologists Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Health Forum United Kingdom Clinical Pharmacy Association United Kingdom Oncology Nursing Society Others Department of Health NHS Leeds South and East CCG NHS England NHS Telford & Wrekin CCG Welsh Government 	Research Institute for the Care of Older People Evidence Review Group Aberdeen HTA Group National Institute for Health Research Health Technology Assessment Programme Associated Guideline Groups National Collaborating Centre for Cancer Associated Public Health Groups Public Health England Public Health Wales NHS Trust

Appendix C

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

_

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.